ALK-POSITIVE LARGE B-CELL LYMPHOMA
Clinical trials for ALK-POSITIVE LARGE B-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new ALK-POSITIVE LARGE B-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for ALK-POSITIVE LARGE B-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug SGR-1505 enters early human testing for blood cancers
Disease control Recruiting nowThis early-phase study tests a new drug called SGR-1505 in about 98 adults with various B-cell blood cancers (like lymphoma and leukemia). The main goals are to check safety and find the best dose. Participants will receive the drug and be monitored for side effects and how the d…
Matched conditions: ALK-POSITIVE LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Schrödinger, Inc. • Aim: Disease control
Last updated May 26, 2026 07:27 UTC
-
New hope for aggressive lymphoma: targeted drug combo under study
Disease control Recruiting nowThis early-phase study tests whether adding the targeted drug polatuzumab vedotin (with or without another drug, glofitamab) to standard chemotherapy is safe for people with untreated, aggressive B-cell lymphoma. About 56 participants will receive the combination to see how well …
Matched conditions: ALK-POSITIVE LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: University of Washington • Aim: Disease control
Last updated May 26, 2026 07:23 UTC